Amprius Sets May 2025 Events Schedule
Special Operations Forces (SOF) Week Date:
Location: Tampa Convention Center; Tampa, FL
Event Details: Amprius will be exhibiting at Booth 3807.
Date: May 19-22, 2025
Location: George R. Brown Convention Center; Houston, TX
Event Details: Amprius will be exhibiting at Booth 3327.
Jefferies 3rd Annual eVTOL/AAM Summit
Date: May 20, 2025
Location: Virtual
Event Details: Amprius President Tom Stepien and CFO Sandra Wallach will meet with investors one-on-one at the event. Amprius CTO Dr. Ionel Stefan will host a fireside chat. If you are interested in scheduling a time to meet with management, please contact your Jefferies representative.
B. Riley Conference
Date: May 21-22, 2025
Location: The Ritz Carlton, Marina Del Rey; Marina del Rey, CA
Event Details: Amprius President Tom Stepien and CFO Sandra Wallach will meet with investors one-on-one at the event. If you are interested in scheduling a time to meet with management, please contact your B. Riley representative.
About Amprius Technologies, Inc.
Amprius Technologies, Inc. is a leading manufacturer of high-energy and high-power lithium-ion batteries, producing the industry's highest-known energy density cells. The Company's commercially available SiMaxx™ batteries deliver up to 450 Wh/kg and 1,150 Wh/L, with third-party validation of 500Wh/kg and 1,300 Wh/L. Amprius expanded its product portfolio to include the SiCore™ platform in 2024, significantly enhancing its ability to serve additional customer applications. The Company's corporate headquarters is in Fremont, California, where it maintains an R&D lab and a MWh scale manufacturing facility for the fabrication of silicon anodes and cells. To serve customer demand, Amprius entered into several agreements to secure over 1.8GWh of contract manufacturing capacity available today. For additional information, please visit amprius.com. Also, see the Company's LinkedIn and Twitter pages.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
25 minutes ago
- Business Insider
UBS Sticks to Its Buy Rating for Targa Resources (TRGP)
In a report released on July 10, Manav Gupta from UBS reiterated a Buy rating on Targa Resources, with a price target of $228.00. The company's shares closed last Friday at $171.90. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Gupta covers the Energy sector, focusing on stocks such as DT Midstream, Cheniere Energy, and Imperial Oil. According to TipRanks, Gupta has an average return of 1.4% and a 60.43% success rate on recommended stocks. In addition to UBS, Targa Resources also received a Buy from Barclays's Theresa Chen in a report issued on July 10. However, on July 7, TD Cowen initiated coverage with a Hold rating on Targa Resources (NYSE: TRGP). TRGP market cap is currently $37.29B and has a P/E ratio of 31.59. Based on the recent corporate insider activity of 70 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TRGP in relation to earlier this year. Most recently, in May 2025, D. Scott Pryor, the President – Logistics and Transportation of TRGP sold 20,000.00 shares for a total of $3,232,750.00.
Yahoo
an hour ago
- Yahoo
Johnson & Johnson (JNJ): I Would 'Love' If Trump Praised The Company, Says Jim Cramer
We recently published . Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the largest and most well-known pharmaceutical companies in the world. Its shares have gained a modest 8.9% year-to-date as the firm has struggled from headwinds such as a judge rejecting its $10 billion talc powder cancer lawsuit settlement. In his previous comments about Johnson & Johnson (NYSE:JNJ), Cramer has called the firm one of the 'best-run companies in America' and praised its balance sheet and drug pipeline. This time around, he discussed the upcoming earnings report and an analyst note: '[On a Mizuho note saying POTUS would praise LLY and JNJ] I would love that, that won't happen. You know why it won't happen? See there's someone in the health and human services department that's not crazy about, about big pharma and the way we think about it. 'JNJ, JNJ I don't know. JNJ's going to report this week they've got a talc problem still but I thought the President was going to act against the plaintiffs, probably has.' A smiling baby with an array of baby care products in the foreground. As for Johnson & Johnson (NYSE:JNJ) 's balance sheet and pipeline, here's what Cramer said: 'Or let's consider Johnson & Johnson, triple A balance sheet, many drugs in the pipeline, one of the best-run companies in America, if not the world, with perhaps the most billion-dollar franchises of any pharmaceutical company I know, but JNJ only yields 3.55%, and it's got this terrible legal overhang related to allegations that its talcum powder, no longer in the market, caused ovarian cancer. We don't know how open-ended the claims are. Can you tolerate that risk? I'd love to say just go buy JNJ, but where? What price? That yield is no longer enough to compensate you for the risk, especially if you don't know if RFK Jr dislikes some of their drug delivery mechanisms and formulas, so people are staying away from that, too, not just because of the bonds. JNJ… 3.3%.' While we acknowledge the potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
2 hours ago
- Business Insider
APA Corp. price target raised to $19 from $17 at Jefferies
Jefferies raised the firm's price target on APA Corp. (APA) to $19 from $17 and keeps a Hold rating on the shares as part of a Q2 preview. The firm expects the company's Q2 report to be solid but slightly below consensus. APA's Egypt oil outlook coupled with Permian cost progress will likely be in focus for investors, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
